In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin

Journal of Microbiology

Volumn 48, Issue 2, 2010, Pages 170-173

  Bayegan, Sedigh ^a   Majoros, Laszlo ^a   Kardos, Gabor ^a   Kemény Beke, Adam ^a   Miszti, Cecilia ^a   Kovacs, Renato ^a   Gesztelyi, Rudolf ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

C. tropicalis; Caspofungin; Murine; Paradoxical growth

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN;

ANIMAL; ARTICLE; ASCITES FLUID; BACTERIAL COUNT; BAGG ALBINO MOUSE; CANDIDA TROPICALIS; CANDIDIASIS; DRUG EFFECT; FEMALE; IMMUNOCOMPROMISED PATIENT; INTRAPERITONEAL DRUG ADMINISTRATION; MICROBIAL VIABILITY; MICROBIOLOGY; MOUSE; SURVIVAL;

ANIMALS; ANTIFUNGAL AGENTS; ASCITIC FLUID; CANDIDA TROPICALIS; CANDIDIASIS; COLONY COUNT, MICROBIAL; ECHINOCANDINS; FEMALE; IMMUNOCOMPROMISED HOST; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; SURVIVAL ANALYSIS;

CANDIDA TROPICALIS; MURINAE; MUS;

EID: 77951986332     PISSN: 12258873     EISSN: 12258873     Source Type: Journal    
DOI: 10.1007/s12275-010-9221-y     Document Type: Article

References (13)

1. Betts, R. F., M. Nucci, D. Talwar, M. Gareca, F. Queiroz-Telles, R. J. Bedimo, R. Herbrecht, and et al. 2009. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin. Infect. Dis. 48, 1676-1684.
2. Clemons, K. V., M. Espiritu, R. Parmar, and D. S. Stevens. 2006. Assessment of paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50, 1293-1297.
3. Cornely, O. A., M. Lasso, R. Betts, N. Klimko, J. Vazquez, G. Dobb, J. Velez, and et al. 2007. Caspofungin for the treatment of less common forms of invasive candidiasis. J. Antimicrob. Chemother. 60, 363-369.
4. Deresinski, S. C. and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis. 36, 1445-1457.
5. Hajdu, R., R. Thompson, J. G. Sundelof, B. A. Pelak, F. A. Bouffard, J. F. Dropinski, and H. Kropp. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743, 872) Antimicrob. Agents Chemother. 41, 2339-2344.
6. Louie, A., M. Deziel, W. Liu, M. F. Drusano, T. Gumbo, and G. L. Drusano. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49, 5058-5068.
7. Ninomiya, M., H. Mikamo, K. Tanaka, K. Watanabe, and T. Tamaya. 2005. Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice. J. Antimicrob. Chemother. 55, 587-590.
8. Pappas, P. G., C. M. F. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, and et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45, 883-893.
9. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46, 12-23.
10. Soczo, G., G. Kardos, I. Varga, B. Kelentey, R. Gesztelyi, and L. Majoros. 2007. In vitro studies with C. tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin. Antimicrob. Agents Chemother. 51, 4474-4476.
11. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48, 3407-3411.
12. Stevens, D. A., M. Ichinomiya, Y. Koshi, and H. Horiuchi. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for caspofungin. Antimicrob. Agents Chemother. 50, 3160-3161.
13. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190, 1494-1471.